相关实验视频
Updated: Feb 28, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
微量营养素缺乏症在第二代基于增生蛋白的肥胖治疗时代
Andrijana Koceva1,2, Andrej Janež3,4, Tajda Pečko5
1Department of Endocrinology and Diabetology, University Medical Center Maribor, 2000 Maribor, Slovenia.
Nutrients
|February 27, 2026
概括
第二代基于隐形素的疗法有助于减肥,但可能会影响营养摄入量. 本综述审查了肥胖管理中的微量营养素状况和风险,并建议营养监测策略.
科学领域:
- 内分泌学 在内分泌学.
- 营养科学 营养科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 第二代基于英克雷丁的疗法对肥胖管理有效,诱导显著的体重减轻.
- 这些疗法主要通过抑制食欲和减少能量摄入来起作用.
- 肥胖通常与基线营养不足有关,这引发了人们对治疗期间微量营养素状况的担忧.
研究的目的:
- 审查肥胖症中的微量营养素脆弱性.
- 综合证据,以饮食摄入量和微量营养素的状态,在incretin-based治疗期间.
- 讨论微量营养素风险的机制,并提出监测策略.
主要方法:
- 现有文献的叙述性审查.
- 综合了关于饮食摄入量,生物化学微量营养素状态和临床结果的数据.
- 讨论潜在的机制和临床监测方法.
主要成果:
- 患有肥胖症的个体通常具有先前存在的微量营养素缺乏.
- 基于因克雷的疗法可能会改变饮食模式和微量营养素暴露.
- 有证据表明,在治疗期间存在特定微量营养素缺乏的潜在风险.
结论:
- 临床医生应该意识到潜在的微量营养素风险,与肥胖症因克列治疗相关.
- 建议对接受这些治疗的患者进行风险分层的营养监测.
- 需要进一步的研究才能充分阐明长期营养影响.
相关概念视频
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
Dipeptidyl Peptidase 4 Inhibitors
786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
672
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
672
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
972
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
972
Oral Hypoglycemic Agents: Glinides
758
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
758

